SGLT-2 Inhibitor and High-Dose Furosemide Plus Small-Volume Hypertonic Saline Solution in Acute HF
A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 544 participants.
Also called NCT06442280
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; single masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 544 participants
- Sponsor
- Registry
-
NCT06442280
-
- Planned start
- (anticipated)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- Not reported
- Registry status
- Unknown status
Technical summary
Registry record NCT06442280. Randomized; single masking; primary purpose treatment. Start 2024-06 (anticipated); primary completion 2026-01-31 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- SGLT-2 Inhibitor and High-Dose Furosemide Plus Small-Volume Hypertonic Saline Solution in Acute HF
- Acronym
- DAPA-TONIC
- Condition
- Heart Failure Acute
- Condition
- Diabetes Type 2
- Intervention (Drug)
- Dapagliflozin tablet
- Intervention (Drug)
- Hypertonic Saline Solution, 1 Ml
- Intervention (Drug)
- Furosemide Injection
- Lead sponsor
- University of Palermo
Record details
- Record id
cardio:ct-nct06442280- Content hash
170fe74980b543d0a34b0d9774fd834f968e9d1e712742350cb1dce51c258d5a